Moderna partners with nonprofit to use mRNA to address global health challenges

Moderna is turning its mRNA tech to even more global health challenges through a partnership with nonprofit research organization IAVI.

The collaboration will focus on developing vaccines and antibodies for HIV/AIDS, tuberculosis, antimicrobial-resistant enteric infections and, of course, COVID-19. IAVI, which focuses on drug discovery for urgent public health threats, will work with the famed biotech and its mRNA platform to advance candidates to help low-income countries where these diseases are common.